Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study.

CONCLUSIONS: ABP 215 is similar to bevacizumab RP with respect to clinical efficacy, safety, immunogenicity, and pharmacokinetics. The totality of evidence supports clinical equivalence of ABP 215 and bevacizumab.
PMID: 30617139 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 7, 2019 Category: Cancer & Oncology Authors: Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares L, Breder V, Ostoros G, Hanes V Tags: Clin Cancer Res Source Type: research